A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed uterine confined endometrioid endometrial adenocarcinoma
with one of the following:

- Grade 2 or 3 carcinoma with more than 50% myometrial invasion (stage IC and IIA)

- Grade 2 or 3 carcinoma with stromal invasion of the cervix (stage IIB)

- No grade I adenocarcinoma

- Less than 50% papillary serous or clear cell histology on pathologic specimen

- Prior hysterectomy (total abdominal, vaginal hysterectomy, or laparoscopic-assisted
vaginal hysterectomy) and bilateral salpingo-oophorectomy with or without additional
surgical staging for endometrial cancer no more than 8 weeks prior to study

- No known metastatic extrauterine metastases, known gross residual disease, positive
peritoneal cytology, or distant metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Zubrod 0-1

Life expectancy:

- Not specified

Hematopoietic:

- Absolute neutrophil count at least 1,800/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 10 g/dL

Hepatic:

- Bilirubin no greater than 1.5 times normal

- SGOT no greater than 3 times normal

Renal:

- Creatinine no greater than 1.5 mg/dL

Cardiovascular:

- No cardiac dysrhythmias

Other:

- No other malignancy within the past 5 years except nonmelanomatous skin cancer

- No medical contraindications to study therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior radiotherapy

Surgery:

- See Disease Characteristics